

# BIOLOGIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS



**BIO079C**  
**January 2015**

Jackson Highsmith  
***Project Analyst***

ISBN: 1-62296-004-1



**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481 USA**  
**866-285-7215 (toll-free within the USA),**  
**or (+1) 781-489-7301**  
**[www.bccresearch.com](http://www.bccresearch.com)**  
**[information@bccresearch.com](mailto:information@bccresearch.com)**

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
METHODOLOGY AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL BIOLOGICS MARKET FORECAST BY TYPE OF PRODUCT, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL BIOLOGICS MARKET FORECAST BY TYPE OF PRODUCT, 2012-2019 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	10
BIOLOGICS NEW PRODUCTS IN DISEASE TREATMENT	10
<i>TABLE 1 SUBCLASSES OF BIOLOGICS DRUGS</i>	11
MONOCLONAL ANTIBODIES	12
<i>FIGURE 1 DIAGRAM OF TYPICAL ANTIBODY STRUCTURE</i>	12
THERAPEUTIC PROTEINS	14
HEMOPOIETIC GROWTH FACTORS (HGFS)	14
Cytokines	15
Blood Factors	15
VACCINES	16
Traditional Vaccines	16
Novel Vaccine Technologies	16
Nanoparticle Delivery of Vaccines	17
MAJOR BIOLOGICS PRODUCT CLASSES	17
<i>TABLE 2 MONOCLONAL ANTIBODY AND THERAPEUTIC PROTEIN DRUGS SUBCLASSES</i>	17
<i>TABLE 3 GLOBAL BIOLOGICS MARKET REVENUE, THROUGH 2019 (\$ MILLIONS)</i>	18
CHALLENGES WITH RNAI	19
ORPHAN DRUG DESIGNATION	20
CHAPTER 4 BIOPHARMACEUTICAL INDUSTRY AND COMPETITIVE ANALYSIS	23
BIOPHARMACEUTICAL INDUSTRY STRUCTURE	23
THE ORIGINS OF BIOTECHNOLOGY	24
INVOLVEMENT OF LARGE PHARMACEUTICAL COMPANIES	25
CHAPTER 5 BIOLOGICS MARKET OVERVIEW	27
<i>TABLE 4 MAJOR PHARMA/BIOPHARMA PLAYERS BY REVENUE, 2013 (\$ MILLIONS)</i>	27
<i>TABLE 5 FDA CLEARED BIOPHARMACEUTICAL PRODUCTS AS OF 2013</i>	28
TOP 25 BIOPHARMACEUTICAL PRODUCT REVENUES	29

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 6 GLOBAL TOP 25 REVENUE GENERATING BIOPHARMACEUTICAL PRODUCTS, 2011-2013 (\$MILLIONS)</i>	29
FDA APPROVED BIOLOGICALS FIRST HALF 2014	31
<i>TABLE 7 FDA APPROVED BIOLOGICALS, JAN. TO JULY 2014</i>	31
TOP 25 BEST SELLING DRUGS 2013	32
<i>TABLE 8 TOP 25 BEST SELLING DRUGS, 2013 (\$ MILLIONS)</i>	32
MONOCLONAL ANTIBODIES	33
<i>TABLE 9 GLOBAL MARKET FORECAST FOR MABS, THROUGH 2019 (\$ MILLIONS)</i>	34
<i>TABLE 10 TOP FIVE LEADING MONOCLONAL ANTIBODY PRODUCTS, 2013 (\$ MILLIONS)</i>	34
<i>TABLE 11 VOLUME OF MAMMALIAN CELL CULTURE PRODUCED MABS, 2014 AND 2019</i>	35
CONJUGATED ANTIBODIES	36
ANTIBODY FRAGMENTS	37
LARGE PHARMACEUTICAL COMPANIES AND BIOPHARMA	37
LARGE PHARMACEUTICAL COMPANY CONSORTIUM FORMED	38
THERAPEUTIC PROTEINS	38
<i>TABLE 12 REVENUE FOR THERAPEUTIC PROTEINS SEGMENT OF BIOLOGICS MARKET, THROUGH 2019 (\$ MILLIONS)</i>	39
HEMOPOIETIC GROWTH FACTORS	40
<i>TABLE 13 LEADING HEMOPOIETIC GROWTH FACTOR BIOLOGIC PRODUCTS, 2013 (\$ MILLIONS)</i>	40
Hemopoietic Growth Factor Clinical Trials	41
<i>TABLE 14 CLINICAL TRIALS ON G-CSF RECEPTORS, 2013-2014</i>	41
CYTOKINES	43
Cytokine Clinical Trials	44
<i>TABLE 15 CLINICAL TRIALS ON CYTOKINES IN 2013 AND 2014</i>	44
ANTIHEMOPHILIA PRODUCTS	46
<i>TABLE 16 TOP REVENUE-GENERATING THERAPEUTIC PROTEIN PRODUCTS, 2013 (\$ MILLIONS)</i>	46
VACCINES	47
Vaccine Market Revenues	47
<i>TABLE 17 VACCINE REVENUES, THROUGH 2019 (\$ MILLIONS)</i>	48
Vaccine Clinical Trials	48
<i>TABLE 18 CLINICAL TRIALS ON VACCINES, 2013-2014</i>	48
CHAPTER 6 IMPACT OF BIOSIMILAR DRUGS ON BIOLOGICS MARKET	52
IMPACT OF BIOSIMILAR DRUGS ON BIOLOGICS MARKET	52
<i>TABLE 19 PATENT AND MARKETING EXCLUSIVITY EXPIRATION FOR TOP SELLING BIOLOGICS, 2009-2018</i>	53
<i>TABLE 20 NUMBER OF BIOSIMILARS PREDICTED TO BE LAUNCHED DURING 2014-2019</i>	54
<i>TABLE 21 TOP 10 BIOLOGICS DRUGS IN WITH GREATEST LEVEL OF BIOSIMILAR COMPETITION, 2013 (\$ MILLIONS)</i>	54
RATIONALE FOR BIOSIMILAR DEVELOPMENT	54
ERYTHROPOIETIN	55
GRANULOCYTE-COLONY STIMULATING FACTOR	55
INTERFERONS	55
HUMAN GROWTH HORMONE	55

<b>TOPIC</b>	<b>PAGE NO.</b>
OPPORTUNITY AND THREAT FROM BIOSIMILARS	56
MARKET TRENDS: GROWTH DRIVERS AND RESISTORS	56
BIOSIMILARS: REGULATORY UPDATE	57
U.S. FDA	57
EUROPEAN BIOSIMILAR REGULATORY GUIDANCE	58
Comparability Testing	59
Potential Problems	59
CHAPTER 7 MAJOR PLAYERS IN BIOLOGIC AND BIOSIMILARS DRUG MARKET	62
MONOCLONAL ANTIBODIES	62
TABLE 22 TOP 10 SELLING MABS, 2013 (\$ MILLIONS)	62
TABLE 23 MAJOR PLAYERS IN MAB MARKET, BY REVENUE, 2013 (\$ MILLIONS)	63
THERAPEUTIC PROTEINS	63
TABLE 24 TOP 10 THERAPEUTIC PROTEIN PRODUCTS, 2013 (\$ MILLIONS)	63
TABLE 25 MAJOR PLAYERS IN THE THERAPEUTIC PROTEINS MARKET BY REVENUE, 2013 (\$ MILLIONS)	64
VACCINES	65
TABLE 26 TOP 10 VACCINES BY REVENUE, 2013 (\$ MILLIONS)	65
CHAPTER 8 GEOGRAPHIC DISTRIBUTION OF BIOLOGICS MARKET	67
GEOGRAPHIC MARKET ANALYSIS	67
CHAPTER 9 PIPELINE ANALYSIS	70
TABLE 27 NEW BIOLOGIC DRUGS APPROVED, 2014	70
TABLE 28 BIOLOGIC DRUGS OBTAINING FDA APPROVAL, 2011-2013	71
BIOSIMILAR DRUGS	78
TABLE 29 RECENT EMA APPROVED BIOSIMILAR DRUGS	78
BIOLOGICS/BIOSIMILARS IN COMPANY PIPELINES, 2013	80
AMGEN	80
TABLE 30 AMGEN BIOLOGICS PIPELINE, 2013	81
TABLE 31 MARKETED AMGEN BIOLOGICALS	81
SANDOZ PHARMACEUTICALS	81
TABLE 32 SANDOZ BIOLOGICS PIPELINE, 2013	82
RELIANCE LIFE SCIENCES	82
TABLE 33 RELIANCE LIFE SCIENCES PIPELINE, 2013	82
BOEHRINGER INGELHEIM	82
TABLE 34 BOEHRINGER INGELHEIM BIOLOGICS PIPELINE, 2013	83
MERCK	83
TABLE 35 MERCK BIOLOGICS PIPELINE, 2013	83
PFIZER	83
TABLE 36 PFIZER BIOLOGICS PIPELINE, 2013	84
SAMSUNG BIOEPIS	84
TABLE 37 SAMSUNG BIOEPIS BIOLOGICS PIPELINE, 2013	84
CLINICAL TRIALS ON BIOLOGICS/BIOSIMILARS	84
TABLE 38 BIOLOGICAL/BIOSIMILAR DRUGS IN CLINICAL TRIALS, 2013-2014	85
CHAPTER 10 BIOLOGICS CLINICAL TRIALS	90

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 39 DESCRIPTION OF PHASES OF CLINICAL TRIALS REQUIRED FOR NEW DRUG APPROVAL (PERCENTAGE SUCCESS RATE)</i>	90
CANCER BIOLOGIC DRUGS	91
<i>TABLE 40 LIST (PARTIAL) OF BIOLOGIC DRUGS IN CLINICAL TRIAL FOR CANCER TREATMENT, 2013-2014</i>	91
GASTROINTESTINAL AND RELATED DISEASES	94
<i>TABLE 41 LIST (PARTIAL) OF BIOLOGIC DRUGS IN CLINICAL TRIAL FOR GI AND RELATED DISEASE TREATMENT, 2013-2014</i>	94
NEUROLOGICAL DISEASE	95
<i>TABLE 42 LIST (PARTIAL) OF BIOLOGIC DRUGS IN CLINICAL TRIAL FOR NEUROLOGICAL DISEASE TREATMENT, 2013-2014</i>	95
CHAPTER 11 MERGERS AND ACQUISITIONS IN BIOLOGICS AREA	98
<i>TABLE 43 LICENSING, DEVELOPMENT AGREEMENTS, ACQUISITIONS AND PARTNERSHIPS IN BIOLOGICS, 2014 (YTD)</i>	98
<i>TABLE 44 LICENSING, DEVELOPMENT AGREEMENTS, ACQUISITIONS AND PARTNERSHIPS IN BIOLOGICS, 2013</i>	100
CHAPTER 12 PATENTS FOR BIOLOGIC DRUGS	106
MONOCLONAL ANTIBODY PATENTS	106
<i>TABLE 45 U.S. PATENTS FOR MONOCLONAL ANTIBODIES</i>	106
THERAPEUTIC PROTEIN PATENTS	109
<i>TABLE 46 PATENTS ISSUED FOR THERAPEUTIC PROTEINS</i>	109
VACCINE PATENTS	111
<i>TABLE 47 PATENTS ISSUED FOR VACCINES (OR VACCINE RELATED PRODUCTS) ASSOCIATED WITH BIOLOGICALS</i>	111
CHAPTER 13 BIOLOGICS MANUFACTURING	116
BIOLOGICS MANUFACTURING	116
BIOPHARMACEUTICAL MANUFACTURING PROCESS	116
THE PREPARATION PROCESS	117
Cell Banking and Seed Culture	117
Production	117
Cell Culture Formats	117
Batch and Continuous Processing	118
Perfusion and Fed-Batch Mode	119
<i>TABLE 48 BIOLOGICS PRODUCTS USING PERFUSION METHOD</i>	119
Perfusion Methods	120
Fed-Batch Methods	120
<i>TABLE 49 BIOLOGICS THERAPEUTIC PRODUCTS USING FED-BATCH METHOD</i>	120
Harvest and Concentration	121
THE FINISHING PROCESS	121
PURIFICATION OF BIOPHARMACEUTICALS	122
AUTOMATED PROCESSING SYSTEMS-SKIDS	123
FORMULATION	124
Lyophilization	124
Cryogranulation	124
Spray Drying	125
Undercooling	125

<b>TOPIC</b>	<b>PAGE NO.</b>
PROCESS INTEGRATION: THE CRITICAL ACTIVITY	125
EXPRESSION SYSTEMS FOR THERAPEUTIC PROTEIN PRODUCTION	126
MICROBIAL THERAPEUTIC PROTEIN PRODUCTION	126
E. COLI ADVANTAGES FOR MICROBIAL PRODUCTION	126
Fast Accumulation	126
Safety Advantage	126
Growth on Inexpensive Carbon Sources	127
Propensity for High-Cell-Density Fermentations	127
Simple Process Scale-Up	127
<i>TABLE 50 MARKETED BIOPHARMACEUTICALS USING E. COLI EXPRESSION SYSTEM, 1997-2014</i>	127
MAMMALIAN CELL THERAPEUTIC PROTEIN PRODUCTION	128
<i>TABLE 51 MARKETED BIOPHARMACEUTICALS USING ANIMAL CELL LINE EXPRESSION SYSTEM</i>	128
EMERGING PRODUCTION SYSTEMS	130
PICHIA AND FILAMENTOUS FUNGI	130
TRANSGENIC PROTEIN PRODUCTION SYSTEMS	131
TRANSGENIC PLANTS	131
<i>TABLE 52 PLANT-BASED TRANSGENIC COMPANIES AND THEIR PIPELINES OF RECOMBINANT PROTEINS</i>	132
TRANSGENIC ANIMALS	133
<i>TABLE 53 THERAPEUTIC PROTEINS PRODUCED IN TRANSGENIC ANIMALS</i>	133
<i>TABLE 54 MARKETED BIOPHARMACEUTICALS USING MURINE (MOUSE) HYBRIDOMA EXPRESSION SYSTEM</i>	134
CHAPTER 14 COMPANY PROFILES	137
ABBVIE INC.	137
BIOLOGICAL PRODUCTS	137
ABBOTT LABORATORIES	137
BIOLOGICAL PRODUCTS	138
ADVAXIS INC.	138
BIOLOGICAL PRODUCTS	139
AGENNIX AG	139
AKEBIA THERAPEUTICS INC.	139
BIOLOGICAL PRODUCTS	140
AMGEN INC.	140
BIOLOGICAL PRODUCTS	141
APOGENIX	141
BIOLOGICAL PRODUCTS	142
APTALIS PHARMACEUTICAL	142
BIOLOGICAL PRODUCTS	142
CHINA BIOLOGIC PRODUCTS	143
BIOLOGICAL PRODUCTS	143
BAXTER BIOSCIENCE INC.	144
BIOLOGICAL PRODUCTS	144
BAYER SCHERING PHARMA AG	145
BIOLOGICAL PRODUCTS	145
BIOGEN IDEC INC.	146

<b>TOPIC</b>	<b>PAGE NO.</b>
BIOLOGICAL PRODUCTS	146
BIOINVENT INTERNATIONAL AB	146
BIOLOGICAL PRODUCTS	147
BIOVITRUM AB (SWEDISH ORPHAN BIOVITRUM AB, SOBI)	147
BIOLOGICAL PRODUCTS	148
CELLEX THERAPEUTICS INC.	148
BIOLOGICAL PRODUCTS	149
CHUGAI PHARMACEUTICALS	149
BIOLOGICAL PRODUCTS	149
CSL BEHRING	150
BIOLOGICAL PRODUCTS	150
DEBIOPHARM GROUP	150
BIOLOGICAL PRODUCTS	151
DENDREON CORP.	151
BIOLOGICAL PRODUCTS	151
DYAX CORP.	152
BIOLOGICAL PRODUCTS	152
ELI LILLY & CO.	153
BIOLOGICAL PRODUCTS	153
ERYTECH PHARMA	153
BIOLOGICAL PRODUCTS	154
GENENTECH INC.	154
BIOLOGICAL PRODUCTS	155
GENMAB A/S	155
BIOLOGICAL PRODUCTS	156
GENZYME	156
BIOLOGICAL PRODUCTS	156
GLAXOSMITHKLINE	157
BIOLOGICAL PRODUCTS	157
GLYCOTOPE GMBH	158
BIOLOGICAL PRODUCTS	158
H. LUNDBECK A/S	159
CURRENT PRODUCTS	159
HAWAII BIOTECH INC.	159
HELIX BIOPHARMA CORP.	160
BIOLOGICAL PRODUCTS	161
HUMAN GENOME SCIENCES INC.	161
BIOLOGICAL PRODUCTS	161
IMCLONE SYSTEMS INC.	162
BIOLOGICAL PRODUCTS	162
IMMUNOGEN INC.	162
BIOLOGICAL PRODUCTS	163
IMMUNOVACCINE TECHNOLOGIES INC.	163
BIOLOGICAL PRODUCTS	164
IMMUTEP S.A.	164
BIOLOGICAL PRODUCTS	164
INNATE PHARMA	165

<b>TOPIC</b>	<b>PAGE NO.</b>
BIOLOGICAL PRODUCTS	165
INTERCELL AG	166
BIOLOGICAL PRODUCTS	166
IPSEN	166
BIOLOGICAL PRODUCTS	167
JANSSEN PHARMACEUTICALS	167
BIOLOGICAL PRODUCTS	168
MEDAREX INC.	168
BIOLOGICAL PRODUCTS	169
MERCK	169
BIOLOGICAL PRODUCTS	169
MERCK SERONO	170
BIOLOGICAL PRODUCTS	170
NOVARTIS AG	170
BIOLOGICAL PRODUCTS	171
NOVO NORDISK A/S	172
BIOLOGICAL PRODUCTS	172
OCTAPHARMA AG	172
BIOLOGICAL PRODUCTS	173
PFIZER INC.	173
BIOLOGICAL PRODUCTS	174
PHARMASTANDARD JSC	174
BIOLOGICAL PRODUCTS	174
PHOSPHAGENICS LTD.	175
BIOLOGICAL PRODUCTS	175
PROTEON THERAPEUTICS INC.	175
RELIANCE LIFE SCIENCES	176
BIOLOGICAL PRODUCTS	177
ROCHE LTD.	177
BIOLOGICAL PRODUCTS	178
SAMSUNG BIOPEPIS	178
BIOLOGICAL PRODUCTS	179
SANOFI-AVENTIS	179
BIOLOGICAL PRODUCTS	179
SEATTLE GENETICS INC.	180
BIOLOGICAL PRODUCTS	180
SHIRE PLC	181
BIOLOGICAL PRODUCTS	181
TEVA PHARMACEUTICAL INDUSTRIES LTD.	182
BIOLOGICAL PRODUCTS	182
THROMBOGENICS NV	183
BIOLOGICAL PRODUCTS	183
UCB S.A.	183
BIOLOGICAL PRODUCTS	184
WILEX AG	184
XCELLEREX INC.	185
ZYMOGENETICS INC.	186



<b>TOPIC</b>	<b>PAGE NO.</b>
BIOLOGICAL PRODUCTS	186

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL BIOLOGICS MARKET FORECAST BY TYPE OF PRODUCT, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 SUBCLASSES OF BIOLOGICS DRUGS	11
TABLE 2 MONOCLONAL ANTIBODY AND THERAPEUTIC PROTEIN DRUGS SUBCLASSES	17
TABLE 3 GLOBAL BIOLOGICS MARKET REVENUE, THROUGH 2019 (\$ MILLIONS)	18
TABLE 4 MAJOR PHARMA/BIOPHARMA PLAYERS BY REVENUE, 2013 (\$ MILLIONS)	27
TABLE 5 FDA CLEARED BIOPHARMACEUTICAL PRODUCTS AS OF 2013	28
TABLE 6 GLOBAL TOP 25 REVENUE GENERATING BIOPHARMACEUTICAL PRODUCTS, 2011-2013 (\$MILLIONS)	29
TABLE 7 FDA APPROVED BIOLOGICALS, JAN. TO JULY 2014	31
TABLE 8 TOP 25 BEST SELLING DRUGS, 2013 (\$ MILLIONS)	32
TABLE 9 GLOBAL MARKET FORECAST FOR MABS, THROUGH 2019 (\$ MILLIONS)	34
TABLE 10 TOP FIVE LEADING MONOCLONAL ANTIBODY PRODUCTS, 2013 (\$ MILLIONS)	34
TABLE 11 VOLUME OF MAMMALIAN CELL CULTURE PRODUCED MABS, 2014 AND 2019	35
TABLE 12 REVENUE FOR THERAPEUTIC PROTEINS SEGMENT OF BIOLOGICS MARKET, THROUGH 2019 (\$ MILLIONS)	39
TABLE 13 LEADING HEMOPOIETIC GROWTH FACTOR BIOLOGIC PRODUCTS, 2013 (\$ MILLIONS)	40
TABLE 14 CLINICAL TRIALS ON G-CSF RECEPTORS, 2013-2014	41
TABLE 15 CLINICAL TRIALS ON CYTOKINES IN 2013 AND 2014	44
TABLE 16 TOP REVENUE-GENERATING THERAPEUTIC PROTEIN PRODUCTS, 2013 (\$ MILLIONS)	46
TABLE 17 VACCINE REVENUES, THROUGH 2019 (\$ MILLIONS)	48
TABLE 18 CLINICAL TRIALS ON VACCINES, 2013-2014	48
TABLE 19 PATENT AND MARKETING EXCLUSIVITY EXPIRATION FOR TOP SELLING BIOLOGICS, 2009-2018	53
TABLE 20 NUMBER OF BIOSIMILARS PREDICTED TO BE LAUNCHED DURING 2014-2019	54
TABLE 21 TOP 10 BIOLOGICS DRUGS IN WITH GREATEST LEVEL OF BIOSIMILAR COMPETITION, 2013 (\$ MILLIONS)	54
TABLE 22 TOP 10 SELLING MABS, 2013 (\$ MILLIONS)	62
TABLE 23 MAJOR PLAYERS IN MAB MARKET, BY REVENUE, 2013 (\$ MILLIONS)	63
TABLE 24 TOP 10 THERAPEUTIC PROTEIN PRODUCTS, 2013 (\$ MILLIONS)	63
TABLE 25 MAJOR PLAYERS IN THE THERAPEUTIC PROTEINS MARKET BY REVENUE, 2013 (\$ MILLIONS)	64
TABLE 26 TOP 10 VACCINES BY REVENUE, 2013 (\$ MILLIONS)	65
TABLE 27 NEW BIOLOGIC DRUGS APPROVED, 2014	70
TABLE 28 BIOLOGIC DRUGS OBTAINING FDA APPROVAL, 2011-2013	71
TABLE 29 RECENT EMA APPROVED BIOSIMILAR DRUGS	78
TABLE 30 AMGEN BIOLOGICS PIPELINE, 2013	81
TABLE 31 MARKETED AMGEN BIOLOGICALS	81
TABLE 32 SANDOZ BIOLOGICS PIPELINE, 2013	82
TABLE 33 RELIANCE LIFE SCIENCES PIPELINE, 2013	82
TABLE 34 BOEHRINGER INGELHEIM BIOLOGICS PIPELINE, 2013	83
TABLE 35 MERCK BIOLOGICS PIPELINE, 2013	83
TABLE 36 PFIZER BIOLOGICS PIPELINE, 2013	84
TABLE 37 SAMSUNG BIOEPIS BIOLOGICS PIPELINE, 2013	84

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 38 BIOLOGICAL/BIOSIMILAR DRUGS IN CLINICAL TRIALS, 2013-2014	85
TABLE 39 DESCRIPTION OF PHASES OF CLINICAL TRIALS REQUIRED FOR NEW DRUG APPROVAL (PERCENTAGE SUCCESS RATE)	90
TABLE 40 LIST (PARTIAL) OF BIOLOGIC DRUGS IN CLINICAL TRIAL FOR CANCER TREATMENT, 2013-2014	91
TABLE 41 LIST (PARTIAL) OF BIOLOGIC DRUGS IN CLINICAL TRIAL FOR GI AND RELATED DISEASE TREATMENT, 2013-2014	94
TABLE 42 LIST (PARTIAL) OF BIOLOGIC DRUGS IN CLINICAL TRIAL FOR NEUROLOGICAL DISEASE TREATMENT, 2013-2014	95
TABLE 43 LICENSING, DEVELOPMENT AGREEMENTS, ACQUISITIONS AND PARTNERSHIPS IN BIOLOGICS, 2014 (YTD)	98
TABLE 44 LICENSING, DEVELOPMENT AGREEMENTS, ACQUISITIONS AND PARTNERSHIPS IN BIOLOGICS, 2013	100
TABLE 45 U.S. PATENTS FOR MONOCLONAL ANTIBODIES	106
TABLE 46 PATENTS ISSUED FOR THERAPEUTIC PROTEINS	109
TABLE 47 PATENTS ISSUED FOR VACCINES (OR VACCINE RELATED PRODUCTS) ASSOCIATED WITH BIOLOGICALS	111
TABLE 48 BIOLOGICS PRODUCTS USING PERFUSION METHOD	119
TABLE 49 BIOLOGICS THERAPEUTIC PRODUCTS USING FED-BATCH METHOD	120
TABLE 50 MARKETED BIOPHARMACEUTICALS USING E. COLI EXPRESSION SYSTEM, 1997-2014	127
TABLE 51 MARKETED BIOPHARMACEUTICALS USING ANIMAL CELL LINE EXPRESSION SYSTEM	128
TABLE 52 PLANT-BASED TRANSGENIC COMPANIES AND THEIR PIPELINES OF RECOMBINANT PROTEINS	132
TABLE 53 THERAPEUTIC PROTEINS PRODUCED IN TRANSGENIC ANIMALS	133
TABLE 54 MARKETED BIOPHARMACEUTICALS USING MURINE (MOUSE) HYBRIDOMA EXPRESSION SYSTEM	134

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL BIOLOGICS MARKET FORECAST BY TYPE OF PRODUCT, 2012-2019 (\$ MILLIONS)	7
FIGURE 1 DIAGRAM OF TYPICAL ANTIBODY STRUCTURE	12